Resminostat (RAS2410)Potent HDAC inhibitor CAS# 864814-88-0 |
- CUDC-101
Catalog No.:BCC2149
CAS No.:1012054-59-9
- RG2833
Catalog No.:BCC1893
CAS No.:1215493-56-3
- Vorinostat (SAHA, MK0683)
Catalog No.:BCC2145
CAS No.:149647-78-9
- LAQ824 (NVP-LAQ824,Dacinostat)
Catalog No.:BCC2160
CAS No.:404951-53-7
- NCH 51
Catalog No.:BCC2422
CAS No.:848354-66-5
- AR-42 (OSU-HDAC42)
Catalog No.:BCC2161
CAS No.:935881-37-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 864814-88-0 | SDF | Download SDF |
| PubChem ID | 11609955 | Appearance | Powder |
| Formula | C16H19N3O4S | M.Wt | 349.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | RAS2410; 4SC-201 | ||
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | (E)-3-[1-[4-[(dimethylamino)methyl]phenyl]sulfonylpyrrol-3-yl]-N-hydroxyprop-2-enamide | ||
| SMILES | CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)C=CC(=O)NO | ||
| Standard InChIKey | FECGNJPYVFEKOD-VMPITWQZSA-N | ||
| Standard InChI | InChI=1S/C16H19N3O4S/c1-18(2)11-13-3-6-15(7-4-13)24(22,23)19-10-9-14(12-19)5-8-16(20)17-21/h3-10,12,21H,11H2,1-2H3,(H,17,20)/b8-5+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Resminostat is a potent inhibitor of HDAC1, HDAC3 and HDAC6, with mean IC50 values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC50 of 877 nM.In Vitro:Resminostat hydrochloride (Resminostat [HCl], 5 μM) induces histone acetylation in myeloma cells. Resminostat hydrochloride displays a substrate competitive binding mode with a mean Ki value of 27 nM. Resminostat hydrochloride (5 μM) induces histone hyperacetylation in myeloma cells. Resminostat inhibits cell growth, induces apoptosis and inhibits MM cell proliferation. Resminostat (5 μM) also modulates expression of bcl-2 family proteins and inhibits Akt pathway signalling downstream of Akt. Resminostat exerts synergistic activity against myeloma cells when combined with common and new anti-myeloma agents[1]. Resminostat inhibits cell growth in head and neck squamous cell carcinoma cell lines, with IC50s ranging from 0.775 μM to 1.572 μM (IC50 for SCC25: 0.775 μM; CAL27: 1.572 μM; and FaDu: 0.899 μM). Resminostat (1.25 and 2.5 μM) has a synergistic effect with irradiation on HNSCC cell lines. Resminostat in combination with cisplatin induces a downregulation of survivin. However, Resminostat shows no effect on Mcl-1 and p-AKT expression[2]. Resminostat reduces viability of HCC cells with the co-treatment of AZD-2014, with IC50s ranging from 0.89 ± 0.12 μM to 0.07 ± 0.01 μM[3]. References: | |||||
Resminostat (RAS2410) Dilution Calculator
Resminostat (RAS2410) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.862 mL | 14.3102 mL | 28.6205 mL | 57.241 mL | 71.5512 mL |
| 5 mM | 0.5724 mL | 2.862 mL | 5.7241 mL | 11.4482 mL | 14.3102 mL |
| 10 mM | 0.2862 mL | 1.431 mL | 2.862 mL | 5.7241 mL | 7.1551 mL |
| 50 mM | 0.0572 mL | 0.2862 mL | 0.5724 mL | 1.1448 mL | 1.431 mL |
| 100 mM | 0.0286 mL | 0.1431 mL | 0.2862 mL | 0.5724 mL | 0.7155 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Resminostat, also known as RAS2410, is a potent inhibitor of histone deacetylase (HDAC) classes I and II (including HDAC1, HDAC3 and HDAC6) with 50% inhibition concentration IC50 values ranging from 43 to 72 nmol/L. Resminostate has the potential to be used for the treatment of multiple myeloma (MM) due to its ability to induce histone H4 hyperacetylation, and apoptosis (IC50 ranging from 2.5 to 3 μmol/L) in MM cells. Recent study results have shown that, in MM cell lines, resminostat abrogates cell growth, suppresses proliferation and induce G0/G1 cell cycle arrest as well as interfering with Akt signaling pathway by decreasing phosphorylation of 4E-BP1 and p70S6k.
Reference
Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol. 2010; 149(4):518-528.
- Gnetucleistol C
Catalog No.:BCN3395
CAS No.:864763-61-1
- Gnetucleistol B
Catalog No.:BCN3585
CAS No.:864763-60-0
- TC-MCH 7c
Catalog No.:BCC6149
CAS No.:864756-35-4
- SB 699551
Catalog No.:BCC7594
CAS No.:864741-95-7
- Sequosempervirin D
Catalog No.:BCN4562
CAS No.:864719-19-7
- Sequosempervirin B
Catalog No.:BCN4777
CAS No.:864719-17-5
- Nigrolineaxanthone V
Catalog No.:BCN4411
CAS No.:864516-31-4
- Sanggenone H
Catalog No.:BCN2946
CAS No.:86450-80-8
- Sanggenone K
Catalog No.:BCN3373
CAS No.:86450-77-3
- BNTX maleate
Catalog No.:BCC6838
CAS No.:864461-31-4
- C 021 dihydrochloride
Catalog No.:BCC6047
CAS No.:864289-85-0
- AMG 548
Catalog No.:BCC6084
CAS No.:864249-60-5
- Leojaponin
Catalog No.:BCN7381
CAS No.:864817-63-0
- BMS-663068
Catalog No.:BCC1428
CAS No.:864953-29-7
- BMS-663068 Tris
Catalog No.:BCC1429
CAS No.:864953-39-9
- Vinblastine
Catalog No.:BCN2376
CAS No.:865-21-4
- Gelsempervine A
Catalog No.:BCN3929
CAS No.:865187-17-3
- AMG837
Catalog No.:BCC6387
CAS No.:865231-46-5
- 4,5-dihydroxy-3,8-dimethylnaphthalene-1,2-dione
Catalog No.:BCN8422
CAS No.:86533-36-0
- FR 180204
Catalog No.:BCC3669
CAS No.:865362-74-9
- N-Methylcalycinine
Catalog No.:BCN4412
CAS No.:86537-66-8
- Benazepril HCl
Catalog No.:BCC5019
CAS No.:86541-74-4
- Benazepril
Catalog No.:BCC4286
CAS No.:86541-75-5
- apigenin 7-O-(6〃-O-malonyl)-β-D-glucoside
Catalog No.:BCN8399
CAS No.:86546-87-4
The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.[Pubmed:20201941]
Br J Haematol. 2010 May;149(4):518-28.
Inhibition of histone deacetylase (HDAC) is a promising mechanism for novel, anti-myeloma agents. We investigated the effects of the novel HDAC inhibitor resminostat on multiple myeloma (MM) cells in vitro. Resminostat is a potent inhibitor of HDACs 1, 3 and 6 [50% inhibitory concentration (IC50)=43-72 nmol/l] representing HDAC classes I and II and induces hyperacetylation of histone H4 in MM cells. Low micromolar concentrations of resminostat abrogated cell growth and strongly induced apoptosis (IC50=2.5-3 micromol/l in 3 out of 4 MM cell lines) in MM cell lines as well as primary MM cells. At 1 micromol/l, resminostat inhibited proliferation and induced G0/G1 cell cycle arrest in 3 out of 4 MM cell lines accompanied with decreased levels of cyclin D1, cdc25a, Cdk4 and pRb as well as upregulation of p21. Resminostat decreased phosphorylation of 4E-BP1 and p70S6k indicating an interference with Akt pathway signalling. Treatment with resminostat resulted in increased protein levels of Bim and Bax and decreased levels of Bcl-xL. Caspases 3, 8 and 9 were activated by resminostat. Furthermore, synergistic effects were observed for combinations of resminostat with melphalan and the proteasome inhibitors bortezomib and S-2209. In conclusion, we have identified potent anti-myeloma activity for this novel HDAC inhibitor.
